Лекарственный мониторинг терапии хронического миелолейкоза иматинибом
Sergey Ivanovich Kutsev, О. С. Оксенюк, Е. Г. Кравченко et al. · Клиническая онкогематология. Фундаментальные исследования и клиническая практика · 2010
Imatinib has shown the high effectiveness in chronic myeloid leukemia (CML) therapy. Recent papers have demonstrated that the achievement of complete cytogenetic response and major molecular response to imatinib therapy may be related with more than 1000 ng/ml imatinib plasma level. Trough plasma concentrations of imatinib (Ctrough) were detected in 551 samples of 442 CML patients. Blood samples were collected 24 b 3h after the last IM dose at 300 (n = 8), 400 (n = 337), 600 mg (n = 155) QD and 12 b 3h after the last IM dose at 800 mg BD(n = 51). Imatinib plasma concentration was determined by a validated LC/ MS/MS method. Rationales for imatinib blood level testing: the patient is not responding as well as the physician would expect, the physician suspects that the patient may be nonadherent to imatinib, the physician suspects that the patient may be experiencing a drug-drug interaction, the patient is experiencing unusually severe side effects. A result of nonadherence to treatment is one of the most important reason of treatment failure or suboptimal response to imatinib (n = 32; 5.8 %). The level of noncompliance increases with higher imatinib doses. Imatinib trough plasma level less than 1000 ng/ml were founded in one half of cases.
Cited by 0 works.
Authors
- Sergey Ivanovich Kutsev
- О. С. Оксенюк
- Е. Г. Кравченко
- Yu. V. Shatokhin
- Е. А. Гранкина
- Ю. С. Богданова
- Е. В. Бурнашева
- Tatiana Chagorova
- Т. Ю. Клиточенко
- Galina Kuchma
- А. С. Лямкина
- Е. P. Мачюлайтене
- Л. И. Напсо
- Н. В. Новоспасская
- Tatiana Ivanovna Pospelova
- И. Н. Самарина
- Olga M. Senderova
- О. Д. Сердюк
- Шамрай Владимир Степанович
- Л. В. Заклякова